Bosly André
Université Catholique de Louvain, Department of Hematology, Mont-Godinne University Hospital, 5530 Yvoir, BELGIUM.
Bull Cancer. 2004 Jul-Aug;91(7-8):E261-73.
In spite of considerable progress in the initial treatment of aggressive non Hodgkin's lymphoma, patients in relapse have poor prognosis. Patients with refractory disease have an even worse outcome. Current strategies and published reports of relapsing patients are presented. Intensification of chemosensitive relapse has yielded a number of continuous second remissions. However considerable efforts are required to define when transplantation should be performed, which type of graft should be used, and what type of post-intensification therapy can be proposed to improve the remission rate and duration.
尽管侵袭性非霍奇金淋巴瘤的初始治疗取得了显著进展,但复发患者的预后较差。难治性疾病患者的结局更差。本文介绍了当前的治疗策略以及复发患者的已发表报告。对化疗敏感的复发患者进行强化治疗已产生了一些持续的第二次缓解。然而,仍需要付出巨大努力来确定何时应进行移植、应使用何种类型的移植物以及可以提出何种类型的强化后治疗以提高缓解率和缓解持续时间。